Description
Coronavirus pandemic has intensely affected the worldwide network. The COVID-19 virulent disease cause by the SARSCoV- 2 has been an extraordinary global health challenge. Through the 24,193,010 globally disturbing 216 countries and 826,141 deaths, because of August 27, 2020. In India, there are 3,310,234 cases with 60,472 deaths. Given the unprecedented magnitude of the pandemic’s impact on health and economy, therapies for COVID-19 are being actively investigated, and there are quite 1000 treatment and over 173 vaccine trials taking place worldwide, including 31 candidate vaccines in clinical evaluation and 142 in pre-clinical evaluation. As of late, the antiviral specialist’s remdesivir and favipiravir, which act by repressing viral replication, have been endorsed for COVID-19 treatment in seriously sick patients by the Government of India.
Dr. S. Azhagu Madhavan, M.Sc., PGDBI., PGDCA., Ph.D., He has completed M.Sc., and Ph.D., Zoology from PG & Research Department of Zoology and Biotechnology, A.V.V.M. Sri Pushpam College (Autonomous), Poondi – Thanjavur Dt., Tamilnadu, India. Research group is involved in studying Cell and Molecular signatures with special reference to Bioinformatics & Statistical tools Software knowledge, Plagiarism Removed and Grammarly software, Mendeley, SPSS, NCBI, Origin pro-8 & Gene & Protein Sequence, Multiple Sequence Analysis, Pathway Analysis, DAVID -Bioinformatics resources & Tools, Molecular Docking Diabetes Mellitus. Our research integrates physiological and pharmacological techniques to study mechanisms underlying development and progressions of Cancer. International Young Scientist Award in“7th International Scientist Awards on Engineering, Science and Medicine” -Jul-2020. Organized by VDGOOD Professional Association, Coimbatore. He has 6 Membership Board and (UGC care list II Approved) 27 journal Editor Associated/Assistant Board member. He has 6 Test Book published and Chapter Book 3 published. Presented 44 papers in National and International conference, lecture workshop and National seminar published 23 Research paper (UGC care list I & II Approved and Web of science) and in well-reputed journals.
COVID -19 CLINICAL FEATURES
Coronavirus pandemic
has intensely affected the worldwide network. The COVID-
19 virulent disease cause by the SARSCoV- 2 has been an
extraordinary global health challenge. Through the
24,193,010 globally disturbing 216 countries and 826,141
deaths, because of August 27, 2020. In India, there are
3,310,234 cases with 60,472 deaths. Given the
unprecedented magnitude of the pandemic’s impact on
health and economy, therapies for COVID-19 are being
actively investigated, and there are quite 1000 treatment
and over 173 vaccine trials taking place worldwide,
including 31 candidate vaccines in clinical evaluation and
142 in pre-clinical evaluation. As of late, the antiviral
specialist’s remdesivir and favipiravir, which act by
repressing viral replication, have been endorsed for
COVID-19 treatment in seriously sick patients by the
Government of India.